

## Not-For-Profit's Patient Assistance Program Receives Favorable Advisory Opinion

### Healthcare Law Update

## Not-For-Profit's Patient Assistance Program Receives Favorable Advisory Opinion

**Carol Grelecki**  
*Member, Healthcare*

**Edward J. Yun**  
*Member, Healthcare*

**Rebecca Falk**  
*Associate, Healthcare*

BRACH | EICHLER<sup>LLC</sup>  
Counsellors at Law



9/30/2024

On August 23, 2024, the Department of Health and Human Services Office of Inspector General (OIG) issued [Advisory Opinion No. 24-07](#), allowing a not-for-profit organization to establish a patient assistance program (PAP) to subsidize cost-sharing obligations for low-income diabetic Medicare enrollees.

The requestor sought to pay the cost-sharing obligations for diabetes drugs for Medicare Part D enrollees who reside in the community it serves. To qualify, Part D enrollees must have no secondary insurance coverage, a household income below 400% of the Federal Poverty Level (FPL) and submit an enrollment application to the requestor. The requestor would allocate funding on a first-come first-serve basis. Under the proposed arrangement, participants can use any pharmacy. However, if participants use a "Preferred Pharmacy," the requestor would pay the cost-sharing up front. Otherwise, participants would pay their cost-share to the pharmacy and receive reimbursement from the requestor.

Although the cost-sharing subsidies and the use of a "Preferred Pharmacy" would each generate remuneration, the OIG issued a favorable opinion, stating that the risk of fraud and abuse is "sufficiently low" for the reasons set forth below.

#### Cost-Sharing Subsidies:

1. The subsidies would not function as a "conduit for payments by a pharmaceutical manufacturer" because the requestor is independent of pharmaceutical influence and does not solicit or receive donations from or on behalf of a pharmaceutical entity.
2. There is a low likelihood that the subsidy would steer Medicare beneficiaries to a particular drug because the subsidy would

apply to all FDA-approved diabetes medications that are covered by Part D.

3. The subsidy would not induce participants to purchase drugs because eligibility is based on strict need-based criteria and is subject to annual re-enrollment and funding limitations.

Enabling Participants to Avoid Out-of-Pocket Expenses by Using a Preferred Pharmacy:

1. The risk of steering patients to a Preferred Pharmacy is low because participants use other factors when selecting a pharmacy, such as location and drug availability, and the dollar value of the subsidy does not differ based on the pharmacy used.

2. The use of a Preferred Pharmacy is unlikely to interfere with clinical decision-making or otherwise induce a participant to purchase a prescription drug.

3. The arrangement is unlikely to increase costs to Federal health care programs because Federal health care programs will pay the same amount, regardless of the pharmacy used.

[Click Here to read the entire September 2024 Healthcare Law Update now!](#)

*For more information, contact:*

**Carol Grelecki** | 973.403.3140 | [cgrelecki@bracheichler.com](mailto:cgrelecki@bracheichler.com)

**Edward J. Yun** | 973.364.5229 | [eyun@bracheichler.com](mailto:eyun@bracheichler.com)

**Rebecca Falk** | 973.364.8393 | [rfalk@bracheichler.com](mailto:rfalk@bracheichler.com)

---

## Authors

The following attorneys contributed to this insight.




**Carol Grelecki**

**Member**

Healthcare Law, Cannabis Industry

973.403.3140 · 973.618.5540 Fax

[cgrelecki@bracheichler.com](mailto:cgrelecki@bracheichler.com)



**Edward J. Yun**

**Member**

Healthcare Law

973.364.5229 · 973.618.5589 Fax

[eyun@bracheichler.com](mailto:eyun@bracheichler.com)



**Rebecca T. Falk**

**Associate**

Healthcare Law

973-364-8393 · 973-618-5923 Fax

[rfalk@bracheichler.com](mailto:rfalk@bracheichler.com)